Tackling an uphill challenge for cancer research | Diaceutics

Tackling an uphill challenge for cancer research

October 16th, 2017



Ewelina Golebiewska of Diaceutics, is swapping her lab coat for lycra in November 2017 as she takes on the uphill challenge of the Padres Pedal The Cause charity cycle race in San Diego, California.

Alongside colleague John McNamara, she’ll be joining Team Pfizer to ride 156 miles over two days in the stunning California landscape. The weekend event donates 100 per cent of the money raised to cancer research projects in San Diego and attracts riders from all corners of cancer care, from survivors, families, doctors and researchers to pharma companies and now, Diaceutics.

Ewelina says, “Cancer will unfortunately affect most of us, whether directly or indirectly. I’ll be riding for my parents, friends and family members who have had, or may have to face cancer one day.”

Ewelina is already a keen cyclist and has climbed hills in the Pyrenees and the Basque Country but the San Diego course will be a new challenge. “The furthest I’ve ridden up to now is 80 miles but to have an 88 mile ride on the Saturday and then get back in the saddle for a 66 mile ride the next day will be something completely new to me. And of course it will be a whole lot warmer than at home in the UK. Hopefully the sunshine will give me that extra push to the finish line.”

In her role as Associate Director at Diaceutics, Ewelina works on multiple targeted assets in diseases such as acute myeloid leukemia, lymphomas, lung and breast cancer so she is delighted to find a different, if more energetic way of contributing to projects that improve new biomarkers, develop targeted therapies and get more patients tested with companion diagnostics at the right time.

She says, “With the advent of precision medicine, immuno-oncology, gene editing and other wonderful advances, I believe we are on the last stretch to beating cancer. But we need to support the amazing scientists and clinicians who got us here to ensure every last patient will have a shot at finding the therapy that works for them in the future.”

To support Ewelina and Padres Pedal The Cause click here.

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications
Facebook
Twitter
YouTube
LinkedIn